A New Path for Weight Loss

Sima Sistani, the CEO of WeightWatchers, unexpectedly stepped down from her position after a two-year tenure. During her time at the company, Sistani took a bold step by embracing weight-loss drugs like Ozempic and Wegovy. She believed that incorporating these medications would help the company stay relevant in the rapidly changing weight loss landscape. However, this move seems to have backfired, as WeightWatchers' shares have plummeted over 90% this year. The company's decision to acquire Sequence, rebranded as WeightWatchers Clinic, allowed it to begin dispensing GLP-1 drugs. This move was met with increased competition from other telehealth companies offering similar services. The popularity of Ozempic and Wegovy has also had a negative impact on WeightWatchers. Despite cutting its full-year sales target and announcing business streamlining measures, the company's stock price continued to decline. This sudden change in fortune has left many wondering what's next for WeightWatchers.